Australie - anglais - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin sodium, quantity: 30 mg - capsule, hard - excipient ingredients: magnesium stearate; purified talc; gelatin; carbon black; titanium dioxide; lactose monohydrate; maize starch; sucrose - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 550 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; sunset yellow fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and noumed cephalexin is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to noumed cephalexin. renal function studies should be perfomed when indicated.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate, quantity: 575 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: sodium starch glycollate; purified talc; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; iron oxide yellow; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic) h. influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic) p. mirabilis; s. faecalis; e. coli (see microbiology). gonorrhoea n. gonorrhoea (non-penicillinase producing). prophylaxis of endocarditis amoxycillin may be used for the prophylaxis of bacterial en

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate, quantity: 288 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: purified talc; sodium starch glycollate; microcrystalline cellulose; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; iron oxide yellow; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic) h. influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic) p. mirabilis; s. faecalis; e. coli (see microbiology). gonorrhoea n. gonorrhoea (non-penicillinase producing). prophylaxis of endocarditis amoxycillin may be used for the prophylaxis of bacterial en

Australie - anglais - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - clindamycin hydrochloride, quantity: 162.87 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; purified talc; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate; carmoisine; patent blue v - clindamycin bnm (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin bnm capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. ,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. ,anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. ,streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. ,staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. ,pneumococci serious respiratory tract infections. ,adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. ,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trandolapril, quantity: 4 mg - capsule, hard - excipient ingredients: dimeticone 350; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; silicon dioxide; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; erythrosine; gelatin; iron oxide black - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trandolapril, quantity: 2 mg - capsule, hard - excipient ingredients: dimeticone 350; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; silicon dioxide; magnesium stearate; titanium dioxide; sunset yellow fcf; purified water; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trandolapril, quantity: 1 mg - capsule, hard - excipient ingredients: dimeticone 350; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; silicon dioxide; magnesium stearate; titanium dioxide; sunset yellow fcf; purified water; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trandolapril, quantity: 0.5 mg - capsule, hard - excipient ingredients: dimeticone 350; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; silicon dioxide; magnesium stearate; titanium dioxide; sunset yellow fcf; quinoline yellow; purified water; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 172.95 mg (equivalent: dabigatran etexilate, qty 150 mg) - capsule, hard - excipient ingredients: dimeticone 350; purified talc; hyprolose; purified water; indigo carmine; hypromellose; carrageenan; acacia; potassium chloride; titanium dioxide; tartaric acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.